NEW YORK (GenomeWeb) – New England Biolabs and TTP have established a non-exclusive partnership to offer services to molecular diagnostic technology developers.

Together, Ipswich, Massachusetts-based NEB and Cambridge, UK-based TTP will offer product-development services spanning instrumentation, consumables, and reagents.

More specifically, the partnership is focused on supporting customers in the MDx and wider life science space to "rapidly transition ideas into commercially successful products," the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.